Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13, Implies 105% Upside

• According to estimates from 13 analysts, Taysha Gene Therapies, Inc. stock's average price target has risen from $12.85 to $13, with forecasts ranging from $10 to $19 per share
• Based on the Jun. 26 closing price, the updated target implies approximately 105% potential upside
• Consensus rating remains at “Buy” across 13 covering analysts, with 13 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Taysha Gene Therapies, Inc. on the , and track all previous and future analyst recommendations for Taysha Gene Therapies, Inc. in the dedicated .

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.